Plenary Sessions
Government Policy and the Biotechnology Industry: BIO Discusses the Key Issues and BIO's Positions
Wednesday, February 23, 2005
7:45 AM
Grand Ballroom
The session will focus on the major policy issues that BIO and the industry expect to face in the coming year including reimbursement, follow-on biologics, drug re-importation and CMS reform.
Moderators:
- Scott Morrison; Life Sciences Partner, Ernst & Young, LLP
- Michael J. Werner, Esquire; Chief of Policy, Biotechnology Industry Organization
Panelists:
- Joshua Boger, PhD; Chairman & CEO, Vertex Pharmaceuticals Inc.
- John C. Martin, PhD; President & CEO, Gilead Sciences, Inc.
- Stephen Sherwin, MD; Chairman & CEO, Cell Genesys, Inc.
- Susan Desmond-Hellman, MD, MPH; President, Product Development, Genentech, Inc.
- Simon Best; Chairman, Ardana Bioscience Ltd.
The Impact of Biotechnology Today - A Clinician's Perspective
Thursday, February 24, 2005
7:45 AM
Grand Ballroom
Leading clinical experts in rheumatology, cardiology, oncology and immunology will discuss the role biotechnology has and will play in the future of medicine.
Moderators:
- Michael King Jr.; Managing Director & Senior Equity Research Analyst, Banc of America Securities LLC
- Tracy T. Lefteroff; Global Managing Partner, Life Science Industry, PricewaterhouseCoopers LLP
Panelists:
- Roman Perez-Soler, MD; Chairman, Department of Oncology, Montefiore Medical Center
- Louis A. Cannon MD FACC, FACP; Founding President, Michigan Cardiovascular Institute
- Roger B. Cohen, M.D.; Director, Phase I Trials, Fox Chase Cancer Center
- Mary K. Crow, MD; Associate Chief for Rheumatology Research at Hospital for Special Surgery
The Last Word: A Biotech Buyside "Watch List" for 2005
Thursday, February 24, 2005
5:30 PM
Empire Room
What is the near-term outlook for investing in the biotechnology sector? This question is always top-of-mind for biotech CEOs and the financial executives who follow and invest in the industry. Leading fund managers will share their views on the projected issues and trends that will affect the industry in 2005. Look for insight into the financing landscape, IPO pricing and the window of opportunity, as well as thoughts on companies and new developments to watch. The audience will have the opportunity to join this open discussion and question the panelists about topics affecting their own companies.
Moderators:
- Maria Luisa Palmese; Partner, Kenyon & Kenyon
Panelists:
- Christopher D. Earl, PhD; Managing Director, Perseus-Soros
- Matthew Perry; Portfolio Manager, Biotechnology Value Fund, L.P.
- Sven H. Borho; Founding General Partner, Orbimed Advisors, LLC